Truist raised the firm’s price target on Edwards Lifesciences to $97 from $84 and keeps a Buy rating on the shares. The company’s “modest” Q4 revenue beat was a positive surprise, though it was offset by an FX driven operating margin miss, the analyst tells investors in a research note. Truist added that its price target increase reflects the recent multiple expansion for the group as well as higher confidence that the TMTT franchise may be reaching an inflection, with an earlier than expected EVOQUE approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
